Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesGT Biopharma Inc

GT Biopharma Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.94 USD -0.02 ( 0.51%)
Last update at 2026-11-11T21:00:00Z
VOLUME
28391
Market Cap
11.76M

Momentum Score

…

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.86
Low
4.03
High
52 Week Price Range
0.35
Low
3.85
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

GT Biopharma is a clinical-stage biotechnology company developing NK-cell engager immunotherapies based on its TriKE platform for hematologic malignancies. Major long-term growth drivers include advancement of its pipeline in clinical studies, licensing or partnerships, and broader adoption of NK-cell approaches; investors may find the platform's targeted mechanism and potential to support multiple programs attractive.
The most important investment risks are its early-stage status, lack of profitability with significant cash burn requiring additional financing, high clinical and regulatory risk, manufacturing scale-up challenges, and intense competition from larger biopharma firms.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.96
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-1377.41%
Net Debt
-6.81M
ROCE
-214.65%
Diluted EPS TTM
-6.68

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -28.35M -13.16M -7.60M -20.88M -58.01M
Net income -28.35M -13.16M -7.60M -20.50M -58.69M
Selling general administrative 8.95M 8.57M 8.23M 12.45M 47.92M
Ebit - -27.53M -7.60M -21.26M -57.52M
Ebitda -34.32M -13.16M 5.98M -20.96M -57.48M
Depreciation and amortization - 14.36M 13.58M 0.29M 0.04M
Operating income -12.42M -14.36M -13.58M -21.26M -57.52M
Other operating expenses 12.42M 14.36M 13.58M 21.26M 57.52M
Interest expense 0.13M 0.00M 0.21M 0.01M 0.72M
Interest income 0.12M 0.40M 0.74M 0.29M 0.04M
Net interest income -0.00M 0.40M 0.52M 0.28M -0.68M
Income tax expense - - -0.01M -0.38M 0.68M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 12.42M 14.36M 13.58M 21.26M 57.52M
Total other income expense net -15.93M 1.20M 5.98M 0.37M -0.50M
Net income from continuing ops -28.35M -13.16M -10.22M -20.88M -58.01M
Net income applicable to common shares - - - - -58.01M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 8.11M 4.23M 14.11M 16.74M 32.17M
Other current assets 1.29M 0.28M 0.08M 0.05M 0.19M
Total liab 2.32M 5.90M 6.63M 5.00M 10.26M
Total stockholder equity 5.79M -1.67M 7.48M 11.73M 21.91M
Other current liab 1.57M 2.05M 2.25M 1.69M 0.14M
Common stock 0.03M 0.00M 0.00M 0.03M 1.15M
Capital stock 0.03M 0.00M 0.00M 0.03M 1.15M
Retained earnings -723.90M -695.23M -682.07M -674.47M -653.58M
Cash 6.81M 3.95M 1.08M 5.67M 8.97M
Total current liabilities 2.32M 5.90M 6.63M 4.94M 10.26M
Current deferred revenue - - - - 1.90M
Net debt -6.81M -3.95M -1.02M -5.50M -8.94M
Short term debt - - 0.06M 0.11M 0.03M
Short long term debt - - - - 0.03M
Short long term debt total - - 0.06M 0.17M 0.03M
Other stockholder equity 729.66M 693.55M 689.54M 686.17M 674.35M
Total current assets 8.11M 4.23M 14.06M 16.56M 32.17M
Net tangible assets - - - - 21.91M
Short term investments - 0.00M 12.89M 10.84M 23.01M
Accounts payable 0.75M 3.85M 4.33M 3.14M 8.19M
Accumulated other comprehensive income - - -0.00M - -
Non currrent assets other - - - 0.01M -
Non current assets total 0.00M 0.00M 0.05M 0.17M 0.00M
Capital lease obligations - 0.00M 0.06M 0.17M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M 12.89M 5.02M 12.14M -23.04M
Change to liabilities - - - - 7.08M
Total cashflows from investing activities - 12.89M - - -23.04M
Net borrowings - - - - 1.21M
Total cash from financing activities 15.78M 2.98M 6.27M -0.22M 42.32M
Change to operating activities - - - - 0.86M
Net income -28.35M -13.16M -7.60M -20.88M -58.01M
Change in cash 2.86M 2.96M -4.59M -3.30M 3.67M
Begin period cash flow 4.04M 1.08M 5.67M 8.97M 5.30M
End period cash flow 6.91M 4.04M 1.08M 5.67M 8.97M
Total cash from operating activities -12.91M -12.90M -8.85M -15.22M -15.61M
Issuance of capital stock 10.51M 2.98M 6.27M 6.27M 24.68M
Other cashflows from investing activities - 12.89M - - -
Dividends paid 0.23M 0.00M - - -
Sale purchase of stock - - -0.00M -0.22M 0.00M
Other cashflows from financing activities 16.00M 2.98M -2.01M -0.04M 42.32M
Change to netincome - - - - 34.47M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital -0.92M 0.83M 1.82M -1.99M 7.94M
Stock based compensation 0.43M 0.23M 2.20M 7.65M 33.93M
Other non cash items 15.93M -0.80M -5.28M 0.01M 0.54M
Free cash flow -12.91M -12.90M -8.85M -15.22M -15.61M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GTBP
GT Biopharma Inc		 -0.02
0.51%		 3.94 - 17.33 204.96 2.02 773.27 -0.09
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

GT Biopharma Inc

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.

315 Montgomery Street, San Francisco, CA, United States, 94104

415 919 4040

https://www.gtbiopharma.com

1

Name Title Year Born
Mr. Michael Martin Breen Interim CEO & Exec. Chairman 1963
Dr. Gregory I. Berk M.D. Pres of R&D, Chief Medical Officer and Member of Scientific Advisor Board 1958
Dr. Gavin S. Choy MBA, PharmD Chief Clinical Devel. Officer NA
Mr. Manu Ohri Chief Financial Officer 1955
Dr. Jeffrey S. Miller M.D. Consulting Chief Scientific Officer & Scientific Advisor NA
Ms. Stacy Herb M.B.A., M.P.H. Sr. VP of Portfolio Management NA
Mr. Michael Martin Breen Interim CEO & Executive Chairman 1963
Mr. Manu Ohri CFO & Secretary 1955
Dr. Jeffrey S. Miller M.D. Consulting Chief Scientific Officer, Consulting Chief Medical Officer & Scientific Advisor NA
Mr. Michael Martin Breen L.L.B. President, CEO & Executive Chairman 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…